top of page
All Posts


Biologics Sterility Assurance: CMC Series XIII—Annex 1, Contamination Control Strategy, and Aseptic Process Simulation
Learn how to build biologics sterility assurance as a lifecycle control system—from Annex 1 and contamination control strategy to barriers, aseptic process simulation, monitoring, testing, and investigations.

Jason Lu
16 minutes ago9 min read


LNP Protein Corona: How Blood Proteins Reshape RNA Delivery
Connect the LNP protein corona, apparent pKa and endosomal escape to understand how targeting moieties and formulation jointly support productive mRNA delivery.

Jason Lu
24 hours ago15 min read


Biologics Raw Material Control: CMC Series XII—Supplier Qualification, Variability, and Adventitious-Agent Risk
Learn how to build a risk-based raw-material control strategy for biologics—from material attributes and supplier qualification to adventitious-agent risk, change management, and CTD evidence.

Jason Lu
Nov 112 min read


mRNA Skin Rejuvenation: How Far Is Elastin Repair from Human Use?
mRNA skin rejuvenation research is moving from protein expression toward tissue repair. What must elastin delivery demonstrate before human benefit can be established?

Jason Lu
Oct 315 min read


MBA Application Tips for Engineers: 5 Ways Technical Professionals Can Show Impact
Technical professionals often have stronger MBA application material than their résumés reveal. These five steps help admissions readers understand how you think, what you own, and what your work makes possible.
Jessica Huang
Oct 268 min read


Biologics Cell Bank Characterization: CMC Series XI—ICH Q5D, MCB/WCB, Genetic Stability, and Cell Substrate Control
Learn how ICH Q5D and Q5B connect cell-line history, MCB/WCB architecture, cell age, identity, purity, genetic stability, and long-term manufacturing suitability.

Jason Lu
Oct 2510 min read


How to Build a Strong MBA Application Story: The 4P Framework
A strong MBA story does not pretend every career decision was perfectly planned. Use the 4P framework to connect your experiences, prove your impact, demonstrate growth, and explain why an MBA is the right next step.
Jessica Huang
Oct 246 min read


Digital Twins in Healthcare: Can SIMCO Model Preterm Birth Prevention?
From the meaning of digital twins in healthcare to AI-enabled counterfactual simulation, this article examines how SIMCO ranks preterm-birth prevention strategies—and what it has not yet proven.

Jason Lu
Oct 2412 min read


ICH Q5A(R2) Viral Safety: Biologics CMC Series X—Testing, Clearance, and Platform Validation
A practical guide to ICH Q5A(R2) Viral Safety, covering cell-substrate risk, adventitious-agent testing, NGS, viral clearance, platform validation, and CTD Module 3.

Jason Lu
Oct 1810 min read


From In Vivo CAR-T to CAR-NK: When Delivery Becomes Immune Regulation
A critical analysis of in vivo CAR-NK, targeted LNP delivery, CAR cell chassis, disease indications, and the path from preclinical evidence to the clinic.

Jason Lu
Oct 1715 min read


Biologics Container Closure Systems: CMC Series IX—CCIT, E&L, and Stability
Container closure systems are part of biologic product quality, sterile-barrier assurance, and dose delivery. This guide connects CCIT, extractables and leachables, vial and prefilled-syringe risks, stability, shipping, in-use studies, and CTD Module 3.

Jason Lu
Oct 119 min read


What Is Prime Editing? From Precise DNA Changes to LNP Delivery and PKU Research
A guide to the CRISPR family and prime editing, explaining RNA and editor engineering, LNP delivery, mouse PKU results, and the evidence still needed for translation.

Jason Lu
Oct 1018 min read


Biologics CMC Series VIII: Biologics Stability Program—An ICH Q5C, Shelf-Life, and Cold-Chain Guide
A passing release result cannot independently support long-term shelf life. This guide connects ICH Q5C with real-time, accelerated, shipping, in-use, and ongoing stability strategies.

Jason Lu
Oct 413 min read


CD1 Lipid Antigen Presentation: How the Immune System Reads Lipid Signals Across Skin Disease, Cancer, and Vaccines
CD1 proteins present lipid antigens as well as peptides: a guide to CD1a skin inflammation, CD1c leukemia TCR-T, and CD1d/iNKT vaccine research.

Jason Lu
Oct 35 min read


Biologics CMC Series VII: Biologics Analytical Method Validation—An ICH Q2(R2) and Q14 Guide
A validated method may still fail to support product decisions. This guide connects ICH Q2(R2), Q14, ATP, potency assays, method transfer, and lifecycle monitoring.

Jason Lu
Sep 2717 min read


AI Drug Discovery Across the R&D Pipeline: What Virtual Biotech Can—and Cannot—Do
From target selection and modality choice to clinical development, this analysis maps where multi-agent AI can help—and where experiments and scientists remain essential.

Jason Lu
Sep 2612 min read


Rebuilding Human Germinal Center B Cells In Vitro: From Antibody Training Ground to a Manipulable Research Platform
A Science Immunology study shows how sequential CD40L, IL-4, and IL-21 signaling generates human germinal center B-like cells in vitro—and what the iGCB platform can and cannot model.

Jason Lu
Sep 2113 min read
Biologics CMC Series, Part 6: Biologics Process Validation — Are Three Batches Enough for Commercial Manufacturing?
Are three batches enough? Explore the process validation lifecycle, PPQ evidence, and continued monitoring through a hypothetical monoclonal antibody program.

Jason Lu
Sep 207 min read


GLP-1 Longevity: Can Semaglutide Mimic Calorie Restriction?
Can semaglutide do more than reduce weight? This article examines new mouse evidence linking GLP-1 signaling, calorie restriction, aging biology and healthspan—and what it could mean for human translation and drug development.

Jason Lu
Sep 137 min read


Biologics CMC Series (5): ICH Q12 Lifecycle Management—Using Established Conditions and PACMPs to Manage Post-Approval Changes
Biologics processes continue to evolve after approval. This guide explains how ICH Q12 uses Established Conditions, PACMPs, PLCM documents, and the PQS to make post-approval CMC changes more predictable and risk-based.

Jason Lu
Sep 616 min read
bottom of page
